Abstract
Viral hepatitis is a common, worldwide problem. It can to a large extent be prevented by strict hygienic measures, and the risk of transmission in certain subgroups of the population can be minimized because potentially infective material such as blood and blood products can be screened for the presence of HBsAg. Passive immunization is of value in some instances. Active immunization against hepatitis B is obviously a major preventive advance, and hopefully we will eventually have effective vaccines against hepatitis A and the other types of viral hepatitis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aldershville J, Dietrichson O, Skinhoj P, Mathiesen LR, Christoffersen P, Nielsen JO (1982) Chronic persistent hepatitis: serological classification and meaning of the hepatitis Be system. Hepatology 2: 243–246
Alexander G, Williams R (1986) Antiviral treatment in chronic infection with hepatitis B. Br Med J 292: 292–294
Anderson MG, Murray-Lyon IM (1985) Natural history of the HBg carrier. Gut 26: 848–860
Billiau A (1986) The mode of action of interferons in viral infections and their possible role in the control of hepatitis B. J Hepatol (in press)
Chadwick RG, Galizzi J, Heathcote J, Lyssiotis T, Cohen BJ, Scheuer PJ, Sherlock S (1979) Chronic persistent hepatitis: hepatitis B virus markers and histological follow-up. Gut 20: 372–377
Cook GC, Mulligan R, Sherlock S (1971) Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 40:159–185
Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, Alberti A, Realdi (1986) Clinical, virological and histologic outcome following seroconversion from HBg to Anti-HBe in chronic hepatitis type B. Hepatology 6: 167–172
Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC (1976) Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 295: 517–522
Hoofnagle JH, Davis GL, Hanson RG (1983) Chronic type B hepatitis: clinical course. In: Verme G, Bonino F, Rizzetto (eds) Viral hepatitis and delta infection. Liss, New York, pp 41–53
Koretz RL, Lewin CJ, Rebhun DJ, Gitnick G (1978) Hepatitis B surface antigen carriers — to biopsy or not to biopsy. Gastroenterology 83: 860–863
Lam KC, Lai CL, Ng RP, Trepo C, Wu PC (1981) Deleterious effect of prednisolone in HBg positive chronic active hepatitis. N Engl J Med 304: 380–386
Liaw YF, Chu CM, Chen TJ, Lin DY, Chang-Chien CS, Wu CS (1982) Chronic lobular hepatitis: a clinicopathological and prognostic study. Hepatology 2: 256–261
Lok ASF, Lai CL, Wu PC (1986) Spontaneous and interferon induced HBe antigen to antibody seroconversion in chronic hepatitis B virus infection in Hong Kong Chinese. J Hepatol (in press)
Novick DM, Lok ASF, Thomas HC (1984) Diminished responsiveness of homosexual men to antiviral therapy for HBg positive chronic liver disease. J Hepatol 1: 29–35
Nowicki MJ, Tong MJ, Nair PV, Stevenson D (1984) Detection of anti-HBc I following prednisolone treatment in patients with chronic active hepatitis B virus infection. Hepatology 4: 1129–1133
Ornata M (1986) In vivo study on mechanism of action of interferon and ARA-A against HBV and DHBV replication in the liver. J Hepatol (in press)
Perrillo R, Regenstein F, Bodicky C, Campbell CR, Sanders GE, Sunwoo YC (1985) Comparative efficacy of adenine arabinoside 5’monophosphate and prednisolone withdrawal followed by adenine arabinoside 5’monophosphate in the treatment of chronic active hepatitis B. Gastroenterology 89: 780–786
Pignatelli M, Waters J, Brown D, Lever A, Schaff Z, Gerety R, Thomas H (1986) HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B infection and during interferon therapy in chronic HBV infection. Hepatology (in press)
Realdi G, Alberti A, Rugge M, Bortolotti F, Rigoli AM, Tremolada F, Ruol A (1980) Seroconversion from hepatitis Be antigen to anti-HBe in chronic hepatitis B infection. Gastroenterology 79:195–199
Rosina F, Saracco G, Actis GC, Brunetto MR, Maran E, Pintus C, Dianzani F, Verme G, Rizzetto M, Bonino F (1986) Treatment of chronic delta hepatitis with alpha-2 recombinant interferon (Abstr). Gastroenterology 90: 1762
Sagnelli E, Piccinino F, Manzillo G, Felaco FM, Filippini P, Maio G, Pasquale G, Izzo CM (1983) Effect of immunosuppressive therapy on HBg-positive chronic active hepatitis in relation to presence or absence of HBg and Anti-HBe. Hepatology 3: 690–695
Sanchez-Tapias JM, Vilar JH, Costa J, Bruguera M, Ballesta AM, Rodes J (1984) Natural history of chronic hepatitis B: relationship between hepatitis B replication and the course of the disease. J Hepatol 1: 15–27
Schalm SW, Summerskill WJH, Gitnick GL, Elveback LR (1976) Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis Bs antigen. Gut 17: 781–786
Schalm SW, Heytink RA, Van Buuren HR, De Man RA (1985) Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B. Lancet II: 358–360
Scullard GH, Pollard RB, Smith JL, Sacks SL, Gregory PB, Robinson WS, Merigan TC (1981) Antiviral treatment of chronic hepatitis B virus infection. Changes in viral markers with interferon combined adenine arabinoside. J Infect Dis 143: 772–773
Scullard GH, Greenberg HB, Smith JL, Gregory PB, Merigan TC, Robinson WS (1982) Antiviral treatment of chronic hepatitis B virus infection: infectious virus cannot be detected in patient serum after permanent responses to treatment. Hepatology 2: 39–49
Soloway RD, Summerskill WHJ, Baggenstoss AH, Geal MG, Gitnick GL, Elveback LR, Schoenfield LJ (1972) Clinical, biochemical and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63: 820–833
Taylor-Papadimitriou J (ed) (1985) Interferons: their impact in biology and medicine. Oxford University Press, Oxford
Thomas HC, Lever AML, Scully LJ, Pignatelli M (1986) Approaches to the treatment of hepatitis B and delta-related liver disease. Semin Liver Dis 6: 34–41
Tsiquaye KN, Collins P, Zuckerman AJ (1986) Screening of antiviral agents for treatment of hepatitis B. J Hepatol (in press)
Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, Robinson WS, Merigan TC, Gregory PB (1984) Survival in chronic hepatitis B: an analysis of 379 patients. Ann Intern Med 101:613–616
Weller IVD, Bassendine MF, Murray AK, Craxi A, Thomas HC, Sherlock S (1982) Effects of prednisolone/azathioprine in chronic hepatitis B infection. Gut 23: 650–655
Yokosuka O, Ornata M, Imazeki F, Hirota K, Mori J, Uchiumi K, Ito Y, Okuda K (1985) Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B. Gastroenterology 89: 246–251
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Heidelberg
About this paper
Cite this paper
McIntyre, N. (1987). Antiviral Treatment of Chronic Hepatitis. In: Okolicsányi, L., Csomós, G., Crepaldi, G. (eds) Assessment and Management of Hepatobiliary Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72631-6_44
Download citation
DOI: https://doi.org/10.1007/978-3-642-72631-6_44
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-72633-0
Online ISBN: 978-3-642-72631-6
eBook Packages: Springer Book Archive